Kyowa Hakko Kirin | 4151

Stock Price
2,515.50
Daily Change
19.50 0.78%
Monthly
7.02%
Yearly
14.19%
Q2 Forecast
2,457.46

EPS Reference Time Actual Consensus Previous
2026-05-07 FY2026Q1 AM 27.56 11.78
2026-02-09 FY2025Q4 AM 65.79 44.43 7.86
2025-10-30 FY2025Q3 AM 31.10 31.06 34.44
2025-07-31 FY2025Q2 AM 19.40 35.51 43.50
2025-05-01 FY2025Q1 AM 11.78 29.00 27.26



Peers Price Chg Day Year Date
M3 1,597.00 2.00 0.13% -3.04% Apr/15
Kyowa Hakko Kirin 2,515.50 19.50 0.78% 14.19% Apr/15
Takeda 5,639.00 35.00 0.62% 34.58% Apr/15
Astellas Pharma 2,566.00 45.00 1.79% 94.03% Apr/15
Sumitomo Dainippon 2,157.00 122.00 6.00% 324.61% Apr/15
Shionogi 3,322.00 -5.00 -0.15% 43.00% Apr/15
Chugai Pharma 8,596.00 76.00 0.89% 27.29% Apr/15
Eisai 4,937.00 87.00 1.79% 27.74% Apr/15
Terumo 2,176.00 20.50 0.95% -17.06% Apr/15
Daiichi Sankyo 2,827.00 93.00 3.40% -9.51% Apr/15

Indexes Price Day Year Date
JP225 58460 582.61 1.01% 72.34% Apr/15

Kyowa Hakko Kirin traded at 2,515.50 this Wednesday April 15th, increasing 19.50 or 0.78 percent since the previous trading session. Looking back, over the last four weeks, Kyowa Hakko Kirin gained 7.02 percent. Over the last 12 months, its price rose by 14.19 percent. Looking ahead, we forecast Kyowa Hakko Kirin to be priced at 2,457.46 by the end of this quarter and at 2,158.61 in one year, according to Trading Economics global macro models projections and analysts expectations.

Kyowa Kirin Co., Ltd., formerly Kyowa Hakko Kirin Co., Ltd. is a Japan-based company principally engaged in the manufacture and sale of medical drugs. The Company operates through two business segments. Pharmaceuticals segment conducts research, development, manufacture and sale of pharmaceuticals and other products. Bio-chemicals segment is involved in the research, development, manufacture and sale of pharmaceuticals and industrial raw materials mainly for amino acid and nucleic acid related substances, as well as healthcare products.